A pharmacogenomic investigation of the cardiac safety profile of ondansetron in children and pregnant women

Britt I. Drögemöller, Galen E.B. Wright, Jessica Trueman, Kaitlyn Shaw, Michelle Staub, Shahnaz Chaudhry, Fudan Miao, Michelle Higginson, Gabriella S.S. Groeneweg, James Brown, Laura A. Magee, Simon D. Whyte, Nicholas West, Sonia M. Brodie, Geert ’t Jong, Sara Israels, Howard Berger, Shinya Ito, Shahrad R. Rassekh, Shubhayan SanataniColin J.D. Ross, Bruce C. Carleton*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

1 Citation (Scopus)

Abstract

Background: Ondansetron is a highly effective antiemetic for the treatment of nausea and vomiting. However, this medication has also been associated with QT prolongation. Pharmacogenomic information on therapeutic response to ondansetron exists, but no investigation has been performed on genetic factors that influence the cardiac safety of this medication. Methods: Three patient groups receiving ondansetron were recruited and followed prospectively (pediatric post-surgical patients n = 101; pediatric oncology patients n = 98; pregnant women n = 62). Electrocardiograms were conducted at baseline, and 5- and 30-min post-ondansetron administration, to determine the effect of ondansetron treatment on QT interval. Pharmacogenomic associations were assessed via analyses of comprehensive CYP2D6 genotyping and genome-wide association study data. Results: In the entire cohort, 62 patients (24.1%) met the criteria for prolonged QT, with 1.2% of the cohort exhibiting unsafe QT prolongation. The most significant shift from baseline occurred at five minutes post-ondansetron administration (P = 9.8 × 10−4). CYP2D6 activity score was not associated with prolonged QT. Genome-wide analyses identified novel associations with a missense variant in TLR3 (rs3775291; P = 2.00 × 10−7) and a variant linked to the expression of SLC36A1 (rs34124313; P = 1.97 × 10−7). Conclusions: This study has provided insight into the genomic basis of ondansetron-induced cardiac changes and has emphasized the importance of genes that have been implicated in serotonin-related traits. These biologically-relevant findings represent the first step towards understanding this adverse event with the overall goal to improve the safety of this commonly used antiemetic medication.

Original languageEnglish
Article number112684
JournalBiomedicine and Pharmacotherapy
Volume148
DOIs
Publication statusPublished - Apr 2022

Keywords

  • CYP2D6
  • Ondansetron
  • Pediatrics
  • Pharmacogenetics
  • Pregnancy
  • QT interval

Fingerprint

Dive into the research topics of 'A pharmacogenomic investigation of the cardiac safety profile of ondansetron in children and pregnant women'. Together they form a unique fingerprint.

Cite this